<DOC>
	<DOCNO>NCT00463203</DOCNO>
	<brief_summary>Irinotecan demonstrate activity malignant glioma multiple phase II study . The activity limit , approximately 15 % response rate progression-free survival 3-5 month . Given synergy irinotecan bevacizumab colorectal cancer , high-level expression vascular endothelial growth factor malignant glioma , one would expect synergy bevacizumab irinotecan glioma . Recent data form small study 32 patient Duke University achieve response rate 62 % patient malignant glioma . Most included patient glioblastomas , regimen may also activity rare primary malignant brain tumor . The investigator therefore plan include primary malignant brain tumor study , clinical activity correlate biomarkers PET result metabolic activity blood flow . This may result information use individualize therapy future .</brief_summary>
	<brief_title>Bevacizumab Irinotecan Patients With Primary Brain Tumors Progression After Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Inclusion criterion : Written inform consent Histological verification primary malignant brain tumor , grade II glioma , meningeoma ependymoma progression treatment option ( include brain stem glioma without histological verification ) Recurrence progression standard treatment ( debulking surgery possible , radiotherapy grade III IV tumor temozolomide chemotherapy . Evidence measurable recurrent progressive disease ( CT/MRI scan ) An interval least 4 week prior surgical resection study enrollment An interval least 4 week prior radiotherapy chemotherapy enrollment protocol . PS 02 ( ECOG scale ) Age &gt; 18 Life expectancy &gt; 3 month Normal organ function : Platelets &gt; 125 x 109/l Hemoglobin &gt; 6,2 mmol/l Leukocytes &gt; 3 x 109/l ACN &gt; 1,5 x 109/l ASAT ALAT &lt; 3 x upper normal limit Bilirubin &lt; 1,5 x upper normal limit Creatinine clearance &gt; 45 ml/min APTT &lt; normal limit INR &lt; normal limit Fertile female must use oral contraceptive , IUD ( intrauterine device ) , gestagen sustain release injection , subdermal implantation , transdermal patch hormonal vaginal ring . This must continue least three month patient offstudy . Fertile male must use preservatives No sign cerebral bleed Exclusion criterion : Radiotherapy chemotherapy within last 4 week . Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid Prior VEGFbased therapy Any condition ( medical , social , psychological ) , would prevent adequate information followup Any concurrent active malignancy , except , adequately treat basal squamous cell carcinoma skin , carcinoma situ . Any significant cardiac disease ( New York Heart Association Class II great ) , arrhythmia , congestive heart failure , acute myocardial infarction within 6 month unstable angina pectoris . Clinically significant peripheral vascular disease Evidence bleeding diathesis , coagulopathy take ASA , NSAIDs clopidogrel Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior day 0 , anticipation need major surgical procedure curse study Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior day 0 History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month prior day 0 History know HIV , Hepatitis B Hepatitis C negative Any ongoing infection , uncontrolled diabetes mellitus , serious nonhealing wound , ulcer bone fracture Pregnancy breast feeding Requires therapeutic anticoagulation Blood pressure &gt; 150/100 mmHG Grade 2 great proteinuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>primary malignant brain tumor</keyword>
	<keyword>grade II glioma</keyword>
	<keyword>meningeoma</keyword>
	<keyword>ependymoma</keyword>
	<keyword>Recurrence progression standard treatment</keyword>
</DOC>